Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an update.
Prescient Therapeutics Limited has announced progress on its share placement, securing approximately $3 million from investors, with $2.5 million already received. The company issued 63,212,500 new ordinary shares as part of this funding effort. This financial boost is expected to support Prescient’s ongoing development of its personalized cancer therapies, potentially strengthening its position in the oncology sector and benefiting stakeholders through enhanced research and development capabilities.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment, including targeted and cellular therapies. The company is known for its innovative products such as PTX-100, a unique GGT-1 inhibitor for T cell lymphomas, and its CellPryme and OmniCAR platforms, which enhance the efficacy and adaptability of cell therapies.
Average Trading Volume: 1,289,921
Technical Sentiment Signal: Sell
Current Market Cap: A$40.06M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.